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a b s t r a c t
Statins, HMG-CoA reductase inhibitors, are considered the ﬁrst line treatment of hyperlipidemia to reduce
the risk of atherosclerotic cardiovascular diseases. The prevalence of hyperlipidemia and the risk of
atherosclerotic cardiovascular diseases are higher in obese patients. Published methods for the quantiﬁcation of statins and their active metabolites did not test for matrix effect of or validate the method
in hyperlipidemic plasma. A sensitive, speciﬁc, accurate, and reliable LC–MS/MS method for the simultaneous quantiﬁcation of simvastatin (SMV), active metabolite of simvastatin acid (SMV-A), atorvastatin
(ATV), active metabolites of 2-hydroxy atorvastatin (2-OH-ATV), 4-hydroxy atorvastatin (4-OH-ATV), and
rosuvastatin (RSV) was developed and validated in plasma with low (52–103 mg/dl, <300 mg/dl) and high
(352–403 mg/dl, >300 mg/dl) levels of triglyceride. The column used in this method was ACQUITY UPLC
BEH C18 column (2.1 × 100 mm I.D., 1.7 m). A gradient elution of mobile phase A (10 mM ammonium
formate and 0.04% formic acid in water) and mobile phase B (acetonitrile) was used with a ﬂow rate
of 0.4 ml/min and run time of 5 min. The transitions of m/z 436.3 → 285.2 for SMV, m/z 437.2 → 303.2
for SMV-A, m/z 559.2 → 440.3 for ATV, m/z 575.4 → 440.3 for 2-OH-ATV and 4-OH-ATV, m/z 482.3 →
258.1 for RSV, and m/z 412.3 → 224.2 for ﬂuvastatin (internal standard, IS) were determined by Selected
Reaction Monitoring (SRM) method to detect transitions ions in the positive ion mode. The assay has a
linear range of 0.25 (LLOQ) −100 ng/ml for all six analytes. Accuracy (87–114%), precision (3–13%), matrix
effect (92–110%), and extraction recovery (88–100%) of the assay were within the 15% acceptable limit
of FDA Guidelines in variations for plasma with both low and high triglyceride levels. The method was
used successfully for the quantiﬁcation of SMV, ATV, RSV, and their active metabolites in human plasma
samples collected for an ongoing clinical pharmacokinetic and pharmacodynamic study on patients prior
to and post gastric bypass surgery (GBS).
© 2018 Elsevier B.V. All rights reserved.

1. Introduction
Statins are a class of cholesterol-lowering medications that are
used for the treatment of high blood cholesterol to reduce the risk of
atherosclerotic cardiovascular diseases. Statins inhibit the enzyme
3-hydroxy-3-methylgluteryl CoA reductase (HMG-CoA reductase),
which is responsible for the conversion of HMG-CoA to mevalonate.
This is the rate limiting step in cholesterol biosynthesis. Inhibition
of cholesterol biosynthesis in the hepatocytes leads to the upregula-
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tion of low density lipoprotein (LDL) receptors in cell membrane of
hepatocytes to maintain cholesterol homeostasis in the liver cells.
The uptake of LDL by the liver leads to a decrease in LDL levels in
the plasma. The inhibition of cholesterol synthesis and the uptake
of LDL from the plasma by hepatocytes from statin treatment, and
the physiological degradation of cholesterol in hepatocytes leads to
an overall reduction in cholesterol levels in the body [1]. According
to the American Heart Association, statins are considered the ﬁrst
line treatment for hyperlipidemia because they are the only drug
class for the treatment of hyperlipidemia that is associated with
reduction in the risk of atherosclerotic cardiovascular diseases [2].
Most obese patients (about 60–70%) suffer from hyperlipidemia
with higher levels of triglycerides and cholesterol in the plasma
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[3]. Substantially higher levels of triglycerides and cholesterol in
the plasma have also been found in lean subjects after consuming
a heavy fatty meal [4]. Triglycerides and cholesterol are the main
lipid components in plasma that contribute to matrix effect issues
in LC/MS-MS analytical assays [5]. In addition, high lipid contents in
the plasma may lead to undesirable effects on the assay speciﬁcity
and recovery [6]. Published methods for the quantiﬁcation of statins
and their metabolites in human plasma are not validated for the
matrix effect in plasma samples from obese subjects or hyperlipidemic plasma. Some regulatory guidelines for bioanalytical method
validation such as European Medicine Agency [7], Health Canada
(which follows EMA 2011 guideline), and Brazilian National Health
Surveillance Agency [8] require the performance of matrix effect
test in “lipemic plasma”, which is plasma with high lipid contents.
However, there are no speciﬁcations in these guidelines on the
lipemic level tested when a bioanalytical method is validated. A
study done by Mayrand-Provencher and his colleagues has concluded that a minimum triglyceride concentration of 300 mg/dl
in the plasma is required to perform a “scientiﬁcally meaningful
lipemic plasma test” [6].
The purpose of this study was to develop a selective and sensitive single assay that is capable of simultaneously analyzing
plasma samples of different statins and their active metabolites,
speciﬁcally, simvastatin (SMV) and its metabolite simvastatin acid
(SMV-A), atorvastatin (ATV) and its two metabolites 2-hydroxy
atorvastatin (2-OH-ATV) and 4-hydroxy atorvastatin (4-OH-ATV),
and rosuvastatin (RSV). These three statins are amongst the most
commonly prescribed cholesterol lowering medications [9]. In
addition, validation of the method using lipemic plasma, with
triglyceride levels ≥300 mg/dl (352–403 mg/dl) was performed to
ensure the reliability of the assay for clinical samples from obese
patients prior to and post their gastric bypass surgery. The developed method has been successfully used for the quantiﬁcation of
the three statins and their active metabolites in clinical samples
from these obese subjects.
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Table 1
Compound-dependent Parameters for SMV, SMV-A, ATV, 2-OH-ATV, 4-OH-ATV,
RSV, and IS in SRM Mode for LC–MS/MS Analysis.
Analyte

Dwell Time (ms)

DPa (V)

EPa (V)

CEa (V)

CXPa (V)

SMV
SMV-A
ATV
2-OH-ATV 4-OH-ATV
RSV
IS

100
100
100
100
100
100

100
100
195
210
100
130

8
7
9
4
9
7

13
11
29
28
41
40

19
16
11
17
12
35

a
DP, declustering potential; EP, entrance potential; CE, collision energy; CXP,
collision cell exit potential.

2.3. Mass spectrometry conditions
LC–MS/MS analysis was performed using an API 5500-Qtrap
triple quadrupole mass spectrometer (Applied Biosystem/MDS
SCIEX, Framingham, MA, USA) equipped with a TurboIonSprayTM
source. The concentrations of SMV, SMV-A, ATV, 2-OH-ATV, 4-OHATV, RSV and IS in plasma samples were determined by Selected
Reaction Monitoring (SRM) method to detect transitions ions in
the positive ion mode. The quantiﬁcations were performed with
the transitions of m/z 436.3 → 285.2 for SMV, m/z 437.2 → 303.2 for
SMV-A, m/z 559.2 → 440.3 for ATV, m/z 575.4 → 440.3 for 2-OH-ATV
and 4-OH-ATV, m/z 482.3 → 258.1 for RSV, and m/z 412.3 → 224.2
for ﬂuvastatin (IS). The main working parameters for mass spectrometer were set as follows: ionspray voltage, 5.5 kV; ion source
temperature, 500 ◦ C; gas1, 20 psi; gas2, 20 psi; curtain gas, 20 psi,
collision gas, high. Compound-dependent parameters for the analytes and the IS were set as summarized in Table 1. By using these
parameters, the positive ion SRM product ion spectra for all the
analytes and the IS were established as shown in Fig. 1.

2.4. Preparation of calibration standards and quality control
samples
2. Materials and methods
2.1. Chemicals and materials
SMV, ATV, ﬂuvastatin, triglyceride mix, and LC–MS grade acetonitrile, water, methanol, ammonium formate (≥99.0%), and
formic acid (∼98%) were purchased from Sigma-Aldrich Corp. (St.
Louis, MO, USA). RSV, SMV-A, 2-OH-ATV, and 4-OH-ATV were purchased from Toronto Research Chemicals Inc. (Toronto, Ontario,
Canada). Blank human plasma was purchased from Equitech-Bio,
Inc. (Kerrville, TX, USA). Ethyl acetate (spectrometric grade, 99.5+%)
was purchased from Alfa Aesar (Ward Hill, MA, USA).

The standard stock solutions of SMV, SMV-A, ATV, 2-OH-ATV, 4OH-ATV, RSV and IS were prepared separately at a concentration of
50 g/ml each in methanol. Stock solutions were stored at −20 ◦ C
until used for the preparation of working solutions. A mixture of
10 g/ml each (SMV, SMV-A, ATV, 2-OH-ATV, 4-OH-ATV, RSV) was
prepared from the stock solutions by a dilution with acetonitrile.
Standard working solutions were prepared by serial dilutions of the
10 g/ml standard working solution mixture with acetonitrile to
obtain concentrations of 0.0025, 0.005, 0.01, 0.025, 0.05, 0.1, 0.25,
0.5, and 1 g/ml. These standard working solutions were used to
spike the plasma samples to yield the calibration standards of 0.25,
0.5, 1, 2.5, 5, 10, 25, 50, and 100 ng/ml.

2.2. Chromatographic conditions
2.5. Plasma sample preparation
Chromatographic analysis was performed using an ultrahigh
performance liquid chromatography system (Waters, Milford, MA,
USA). SMV, SMV-A, ATV, 2-OH-ATV, 4-OH-ATV, RSV and ﬂuvastatin
(internal standard; IS) were separated on ACQUITY UPLC BEH C18
column (2.1 × 100 mm I.D., 1.7 m). The mobile phases consisted of
10 mM ammonium formate and 0.04% formic acid in water (mobile
phase A) and acetonitrile (mobile phase B). A gradient elution was
used for the separation as follows: 0–1 min, 30% B; 1–1.5 min,
30–60% B; 1.5–2 min, 60–80% B; 2–2.5 min, 80–95% B; 2.5–3 min,
95% B; 3–3.5 min 95–80% B; 3.5–4 min, 80% B; 4–4.5 min, 80–60%
B; 4.5–5 min, 60–30% B. The elution was performed at a ﬂow rate
of 0.4 ml/min, with injection volume of 5 l, sample temperature
of 20 ◦ C, and column temperature of 40 ◦ C.

Liquid–liquid extraction was used for plasma samples preparation. A plasma sample (200 l) was spiked with 10 l of triglyceride
mixture (as needed for lipemic group) and 20 l of IS (500 ng/ml in
acetonitrile). Blank plasma samples were also spiked with 20 l of
the required analyte concentrations to prepare the samples for calibration curve of individual analytes and the quality control samples.
Ethyl acetate (1 ml) was then added, and the mixture was vortexed
for 3 min. After centrifugation with 17,968 × g for 20 min at 4 ◦ C,
the upper phase was transferred to another vial and evaporated to
dryness in a stream of air at room temperature (25 ◦ C). The residue
was reconstituted in 100 l of water/acetonitrile (70:30 v/v) for
LC–MS/MS analysis.
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Fig. 1. Representative SRM positive product ion mass spectra for (a) SMV, (b) SMV-A, (c) ATV, (d) 2-OH-ATV and 4-OH-ATV, (e) RSV, and (f) IS. The transitions were m/z 436.3
→ 285.2 for SMV, m/z 437.2 → 303.2 for SMV-A, m/z 559.2 → 440.3 for ATV, m/z 575.4 → 440.3 for 2-OH-ATV and 4-OH-ATV, m/z 482.3 → 258.1 for RSV, and m/z 412.3 →
224.2 for IS.

2.6. Method validation
Method validation was performed according to the US FDA
Guidelines of “Bioanalytical Method Validation: Guidance for
Industry” [10] for (1) selectivity and speciﬁcity, (2) sensitivity and
carryover, (3) linearity, (4) accuracy and precision, (5) extraction
recovery (6) matrix effect, and (7) stability. Each analytical run
included samples of double blank plasma (no analytes nor IS), blank

(no analytes, with IS), and calibration standards. Replicate sets of
quality control samples were included in the run.
2.6.1. Selectivity and speciﬁcity
Selectivity and speciﬁcity were evaluated by analyzing six different lots of un-pooled blank human plasma matrix samples
with triglyceride levels of 52–103 mg/dL. The same six lots were
spiked with triglyceride mixture (to reach 352–403 mg/dL), and
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the selectivity and speciﬁcity were assessed in the presence of high
triglyceride levels. The double blank samples should not have any
interference at the retention time of each analyte and the IS.
2.6.2. Sensitivity and carryover
Sensitivity was assessed by analyzing six replicates of spiked
LLOQ samples, with accuracy and precision within 20% of the
nominal concentration of the LLOQ. The LLOQ was determined as
the concentration producing a peak response of at least 5:1 the
response of blank plasma at the same retention time. Carryover
was assessed by injecting 5 samples at the high QC concentration
followed by three blank injections. Carryover acceptance criteria is
less than 20% of the LLOQ response.
2.6.3. Linearity
Linear calibration curves were constructed by plotting the peak
area ratios of each analyte/IS versus the analyte concentrations over
the range of 0.25–100 ng/ml. The linearity was assessed using linear
regression analysis. Calibration curves were constructed in plasma
with low and high triglyceride levels.
2.6.4. Accuracy and precision
Quality control samples, containing LLOQ, low (LQC), medium
(MQC), and high (HQC) concentrations of 0.25, 0.5, 5, and 80 ng/ml,
respectively, of each analyte were used to establish the accuracy
and precision of the assay. Quality control samples used for the
determination of accuracy and precision were prepared from a
stock solution different from the one used to prepare the calibration
curve samples. Both intra-day and inter-day accuracy and precision
were evaluated by analyzing six replicates of the four different concentrations on three different days. The accuracy was expressed as
a percentage of the nominal concentration, and the precision was
expressed by the % of coefﬁcient of variation. The acceptable criteria for accuracy is ±15% and the precision is ≤15% except at LLOQ,
where the acceptable deviation is up to 20% in accuracy and precision. The accuracy and precision of the method were assessed in
plasma with low and high triglyceride levels.
2.6.5. Extraction recovery
Recovery of the analytes and the IS from the extraction method
was evaluated by comparing the peak areas of each analyte and
the IS between two samples, where the plasma was spiked with
the analytes mixture after and before the extraction (six each of
LQC, MQC and HQC), respectively. Recovery does not need to be
100%, according to FDA guidelines, but should be consistent, precise, and reproducible. Extraction recovery was performed with low
and high triglyceride levels for each analyte. For the IS, extraction
recovery from high triglyceride plasma was performed.
2.6.6. Matrix effect
Matrix effect was evaluated by comparing the peak areas of each
analyte in plasma samples that were extracted before spiking the
analyte with that in neat solution. Matrix effect was determined
using six different sources of plasma at the three different QC concentrations. At ﬁrst, matrix effect was performed with plasma from
six different individuals with triglyceride levels of 52–103 mg/dL.
The test was repeated with plasma that was spiked with a known
concentration of triglycerides to reach concentrations more than
300 mg/dl (352–403 mg/dl). Matrix effect on the IS was assessed
using the plasma with high triglyceride levels.
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to room temperature. Bench-top stability was assessed after the QC
samples were kept at room temperature for 4 h. Long-term stability was assessed after the QC samples were kept at −80 ◦ C for one
month. Processed sample stability was determined by the quantiﬁcation of QC samples prior to and after storage in the autosampler
(20 ◦ C) for 24 h. Stock solution stability was determined by comparing the analysis results of samples freshly prepared and after
storage at −20 ◦ C for 1 month.
2.7. Pharmacokinetic study
Clinical samples were collected from obese patients (one sample/patient at each visit) before undergoing GBS (baseline), and at
follow-up visits at 3, 6, and 12 months after the surgery. Twenty-six
patients had been taking one of the statins at various doses, 10, 20,
40, or 80 mg for SMV, 10, 40, or 80 mg for ATV, or 5, 10, 20, or 40 mg
for RSV. The sample collection time was at different time points
after dose for each patient. The samples were collected from obese
patients as a part of another ongoing clinical study aimed to explore
the impact of GBS on the pharmacokinetics and pharmacodynamics of SMV, ATV and RSV. All samples were stored at −80 ◦ C until
analysis. Twenty patients were not on any statin and were used as
a control group for the pharmacodynamic parameters.
2.8. Statistical analysis
®

Statistical analysis was performed using SPSS Version 22, with
signiﬁcant level set at p < 0.05. Inter-day and inter-day accuracy,
precision, extraction recovery, and matrix effect results were compared at each QC concentration level by Student’s t-test between
plasma containing low and high triglycerides. Demographic data
of age between statin and non-statin groups was compared using
Student’s t-test.
3. Results
3.1. Selectivity and speciﬁcity
The degrees of interference by endogenous plasma constituents
with all the analytes and the IS were evaluated by analyzing processed blank plasma with low and high triglyceride levels by
inspecting the resulted chromatograms. No signiﬁcant interference
was observed in the blank plasma chromatograms (in plasma with
either low or high triglyceride levels) at the retention times of SMV
(3.8 min), SMV-A (3.6 min), ATV (3.2 min), 2-OH-ATV (3.1 min), 4OH-ATV (2.8 min), RSV (2.9 min) and the IS (3.3 min) as shown in
Fig. 2. There was a peak from an endogenous substance at 3.6 min
when monitoring the transition for rosuvastatin in blank plasma,
but it did not interfere with the quantiﬁcation of rosuvastatin which
elutes at 2.9 min.
3.2. Sensitivity
The LLOQ for all analytes was 0.25 ng/ml yielding a
response/baseline ratio of >5 for each analyte compared to
blank plasma. The chromatograms for all six analytes at LLOQ is
represented in Fig. 2. No carryover (<10% of LLOQ signal for all
analytes) was observed in the blank injection following 5 injections
of samples at the high QC concentration.
3.3. Linearity

2.6.7. Stability
Tests on freeze and thaw, bench-top, long-term, processed sample, and stock solution stability were performed using six replicates
at each of the QC concentration levels. Freeze and thaw stability
was determined after three cycles of freeze and thaw from −80 ◦ C

The calibration curves were linear over the concentration range
of 0.25–100 ng/ml for all the analytes in plasma with both low and
high triglyceride levels. Linear regression equations with a weighting factor of 1/x of the analyte to the IS concentrations produced the
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Fig. 2. Representative chromatograms of (a) blank plasma, (b) IS, and (c) the six analytes at LLOQ of 0.25 ng/ml in plasma with low (left panel) and high (right panel)
triglyceride levels. The retention times for SMV, SMV-A, ATV, 2-OH-ATV, 4-OH-ATV, RSV, and IS are 3.8, 3.6, 3.2, 3.1, 2.8, 2.9, and 3.3 min, respectively.
Table 2
Linearity of the Calibration Curves for SMV, SMV-A, ATV, 2-OH-ATV, 4-OH-ATV, and RSV in Plasma with Low and High Triglyceride Levels [Data are Presented as Mean ± SD
(% CV)].
Low TG Levels (n = 6)

High TG Levels (n = 4)
2

Analyte

Slope

r

Slope

r2

SMV
SMV-A
ATV
2-OH-ATV
4-OH-ATV
RSV

0.045 ± 0.004 (7.94)
0.014 ± 0.001 (8.85)
0.086 ± 0.009 (9.94)
0.053 ± 0.005 (8.68)
0.019 ± 0.002 (9.69)
0.018 ± 0.001 (7.53)

0.987 ± 0.009 (0.92)
0.991 ± 0.007 (0.72)
0.991 ± 0.005 (0.51)
0.990 ± 0.004 (0.43)
0.990 ± 0.006 (0.56)
0.991 ± 0.006 (0.64)

0.051 ± 0.002 (4.07)
0.013 ± 0.001 (7.97)
0.085 ± 0.004 (4.43)
0.049 ± 0.002 (3.39)
0.020 ± 0.001 (6.04)
0.017 ± 0.001 (6.83)

0.990 ± 0.008 (0.75)
0.990 ± 0.004 (0.42)
0.994 ± 0.003 (0.28)
0.994 ± 0.001 (0.12)
0.991 ± 0.004 (0.24)
0.995 ± 0.001 (0.15)
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Table 3
Intra-day (3 different days) and Inter-day Accuracy and Precision of SMV, SMV-A, ATV, 2-OH-ATV, 4-OH-ATV, and RSV at LLOQ and Three QC Concentration Levels for Plasma
with Low Triglyceride Levels.
Concentration
(ng/ml)

SMV
0.25
0.5
5
80
SMV-A
0.25
0.5
5
80
ATV
0.25
0.5
5
80
2-OH-ATV
0.25
0.5
5
80
4-OH-ATV
0.25
0.5
5
80
RSV
0.25
0.5
5
80

Day 1 (n = 6)

Day 2 (n = 6)

Day 3 (n = 6)

Inter-day (n = 18)

Accuracy (%)
Mean ± SD

Precision (%)

Accuracy (%)
Mean ± SD

Precision (%)

Accuracy (%)
Mean ± SD

Precision (%)

Accuracy (%)
Mean ± SD

Precision (%)

101.30 ± 7.52
97.53 ± 4.88
104.38 ± 7.92
103.50 ± 6.44

7.42
5.00
7.59
6.22

96.80 ± 3.56
103.95 ± 5.42
95.53 ± 7.36
98.07 ± 6.09

3.68
5.21
7.71
6.21

99.70 ± 5.40
99.00 ± 6.82
95.72 ± 4.88
100.22 ± 8.12

5.41
6.89
5.10
8.10

99.27 ± 5.71
100.16 ± 6.11
98.54 ± 7.71
100.59 ± 6.91

5.75
6.10
7.82
6.87

97.58 ± 8.53
102.22 ± 6.13
101.05 ± 8.80
96.30 ± 8.49

8.75
5.99
8.71
8.81

103.13 ± 12.81
94.72 ± 5.72
97.15 ± 4.93
101.70 ± 4.85

12.42
6.04
5.08
4.77

99.32 ± 4.64
97.65 ± 6.96
97.98 ± 7.33
98.67 ± 6.65

4.67
7.13
7.48
6.74

100.01 ± 9.04
98.19 ± 6.71
98.73 ± 6.98
98.89 ± 6.80

9.04
6.83
7.07
6.88

104.02 ± 6.69
95.95 ± 8.79
102.63 ± 12.43
100.22 ± 5.32

6.43
9.16
12.11
5.31

109.43 ± 9.17
97.48 ± 7.07
100.75 ± 9.48
97.68 ± 7.00

8.38
7.25
9.41
7.17

103.50 ± 6.47
95.05 ± 9.07
98.57 ± 8.28
100.67 ± 4.89

6.25
9.54
8.40
4.85

105.65 ± 7.61
96.16 ± 7.92
100.65 ± 9.74
99.52 ± 5.62

7.20
8.23
9.68
5.65

102.93 ± 8.41
103.35 ± 7.74
100.27 ± 7.63
98.28 ± 5.22

8.17
7.49
7.61
5.31

104.05 ± 6.63
97.95 ± 9.41
101.63 ± 10.81
99.68 ± 5.71

6.37
9.61
10.63
5.73

101.25 ± 6.23
99.17 ± 10.70
98.55 ± 10.47
102.17 ± 4.31

6.15
10.79
10.62
4.22

102.74 ± 6.82
100.16 ± 9.11
100.15 ± 9.24
100.04 ± 5.08

6.64
9.10
9.23
5.08

97.18 ± 3.55
98.18 ± 7.23
102.52 ± 3.76
95.90 ± 9.57

3.65
7.37
3.67
9.98

105.67 ± 7.34
98.58 ± 9.09
101.27 ± 9.09
95.02 ± 7.80

6.95
9.22
8.97
8.21

104.15 ± 9.25
95.60 ± 9.67
98.32 ± 8.72
100.58 ± 4.02

8.89
10.12
8.87
4.00

102.33 ± 7.69
97.46 ± 8.31
99.81 ± 7.40
97.17 ± 7.48

7.52
8.53
7.41
7.70

99.00 ± 12.37
101.85 ± 7.71
98.65 ± 10.96
99.68 ± 7.03

12.50
7.57
11.11
7.05

104.75 ± 4.60
100.28 ± 10.04
96.30 ± 9.85
97.03 ± 4.96

4.39
10.02
10.23
5.12

96.20 ± 8.37
102.30 ± 10.16
96.58 ± 3.23
102.15 ± 4.89

8.70
9.93
3.34
4.79

99.98 ± 9.23
101.48 ± 8.85
97.18 ± 8.25
99.62 ± 5.78

9.24
8.72
8.49
5.81

best ﬁt equations for the concentration-detector response relationship. The mean ± SD coefﬁcients of determination (r2 ) and slopes
of the calibration curves from inter-day batches are presented in
Table 2.

3.4. Accuracy and precision
Accuracy and precision data for intra- and inter-day plasma
samples of SMV, SMV-A, ATV, 2-OH-ATV, 4-OH-ATV, RSV are presented in Tables 3 and 4 for plasma with low and high triglyceride
levels, respectively. The assay values for intra-day and inter-day
accuracy and precision for plasma with either low or high triglyceride levels were within the acceptable 15% limit. The intra-day
accuracy and precision values for plasma with low triglycerides
ranged from 96 to 104% and 4 to 8% for SMV, 95 to 103% and 5 to
12% for SMV-A, 95 to 109% and 5 to 12% for ATV, 98 to 104% and 4
to 11% for 2-OH-ATV, 95 to 106% and 4 to 10% for 4-OH-ATV, 96 to
105% and 3 to 13% for RSV. The assay values for inter-day accuracy
and precision for plasma with low triglycerides ranged from 99 to
101% and 6 to 8% for SMV, 98 to 100% and 7 to 9% for SMV-A, 96 to
106% and 6 to 10% for ATV, 100 to 103% and 5 to 9% for 2-OH-ATV,
97 to 102% and 7 to 9% for 4-OH-ATV, 97 to 101% and 6 to 9% for RSV
(Table 3). High triglyceride levels in the plasma did not affect the
inter- or intra-day accuracy and precision of the method. The values for the intra-day accuracy and precision for plasma with high
triglycerides ranged from 94 to 104% and 4 to 13% for SMV, 93 to
103% and 4 to 11% for SMV-A, 87 to 104% and 3 to 13% for ATV, 90
to 114% and 5 to 11% for 2-OH-ATV, 89 to 100% and 5 to 12% for
4-OH-ATV, 93 to 102% and 6 to 14% for RSV. The assay values for
inter-day accuracy and precision for plasma with high triglycerides
ranged from 98 to 99% and 6 to 10% for SMV, 95 to 100% and 7 to
10% for SMV-A, 98 to 99% and 8 to 11% for ATV, 96 to 103% and 8 to

12% for 2-OH-ATV, 93 to 98% and 6 to 10% for 4-OH-ATV, 94 to 99%
and 7 to 11% for RSV (Table 4).
3.5. Extraction recovery
The mean (± SD) extraction recovery are presented in Table 5.
The recovery of the analytes from plasma samples with low triglyceride levels was between 98–100% for SMV, 88–96% for SMV-A,
97–100% for ATV, 92–98 for 2-OH-ATV, 97–99% for 4-OH-ATV, and
88–95 for RSV. The recovery of the analytes from plasma samples
with high triglyceride levels were comparable to those from plasma
with low triglyceride levels, 95–97% for SMV, 91–98% for SMV-A,
93–97% for ATV, 95–97 for 2-OH-ATV, 95–97% for 4-OH-ATV, and
94–98 for RSV. The extraction recovery was reproducible at the
three QC concentration levels. The extraction recovery for the internal standard was 88.12 ± 7.84% from plasma with high triglyceride
levels. Since the extraction recovery of the IS from high TG plasma
was above 85%, we did not test for the extraction recovery using
low TG plasma.
3.6. Matrix effect
No signiﬁcant matrix effect was observed in plasma samples
with low triglyceride concentrations. Matrix effect was negligible
(within ±10%) at the three QC concentration levels, with a range
of 93–110%. When plasma spiked with triglycerides to reach levels higher than 300 mg/dl (352–403 mg/dl) was used in the matrix
effect test, the matrix effect ranged 92–103%, similar to those with
plasma of low triglyceride levels (Table 6). The assay value for
matrix effect on the IS was 93.51 ± 6.67 for plasma with high triglyceride levels. Matrix effect was negligible for the IS in plasma with
high TG levels, so the test was not repeated in plasma with low TG
levels.
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Table 4
Intra-day (3 different days) and Inter-day Accuracy and Precision of SMV, SMV-A, ATV, 2-OH-ATV, 4-OH-ATV, and RSV at LLOQ and Three QC Concentration Levels for Plasma
with High Triglyceride Levels.
Concentration
(ng/ml)

SMV
0.25
0.5
5
80
SMV-A
0.25
0.5
5
80
ATV
0.25
0.5
5
80
2-OH-ATV
0.25
0.5
5
80
4-OH-ATV
0.25
0.5
5
80
RSV
0.25
0.5
5
80

Day 1 (n = 6)

Day 2 (n = 6)

Day 3 (n = 6)

Inter-day (n = 18)

Accuracy (%)
Mean ± SD

Precision (%)

Accuracy (%)
Mean ± SD

Precision (%)

Accuracy (%)
Mean ± SD

Precision (%)

Accuracy (%)
Mean ± SD

Precision (%)

98.53 ± 8.73
101.20 ± 12.69
97.67 ± 5.16
99.79 ± 7.56

8.86
12.54
5.28
7.57

98.00 ± 7.10
95.20 ± 6.08
93.63 ± 7.90
95.02 ± 5.04

7.25
6.39
8.44
5.30

97.61 ± 8.72
96.23 ± 10.69
104.28 ± 3.90
98.70 ± 5.60

8.93
11.11
3.74
5.68

98.05 ± 7.73
97.54 ± 9.96
98.53 ± 7.14
97.84 ± 6.16

7.88
10.21
7.25
6.29

102.33 ± 8.73
100.80 ± 10.15
96.20 ± 7.67
96.47 ± 7.77

8.53
10.07
7.98
8.06

101.00 ± 6.48
95.07 ± 8.43
99.32 ± 7.91
93.37 ± 3.45

6.42
8.86
7.97
3.69

98.08 ± 7.84
102.50 ± 11.55
93.68 ± 7.75
96.28 ± 8.16

7.99
11.27
8.28
8.47

100.47 ± 7.50
99.46 ± 10.06
96.40 ± 7.68
95.37 ± 6.55

7.46
10.11
7.97
6.87

101.64 ± 3.03
95.87 ± 8.17
101.97 ± 9.05
95.52 ± 7.75

2.98
8.52
8.87
8.11

87.42 ± 4.70
100.30 ± 12.96
101.49 ± 9.03
99.18 ± 8.75

5.37
12.92
8.90
8.82

104.04 ± 12.75
100.17 ± 9.75
93.70 ± 8.25
101.82 ± 6.10

12.25
9.73
8.80
5.99

97.70 ± 10.68
98.78 ± 10.07
99.05 ± 9.13
98.84 ± 7.63

10.93
10.20
9.21
7.72

100.83 ± 6.94
90.72 ± 9.71
97.70 ± 5.01
93.85 ± 7.75

6.88
10.71
5.13
8.26

111.00 ± 6.72
103.37 ± 8.28
100.76 ± 9.00
93.42 ± 6.53

6.06
8.01
8.94
6.99

89.93 ± 6.08
113.67 ± 7.03
93.32 ± 10.21
100.18 ± 6.34

6.77
6.19
10.94
6.33

100.59 ± 10.80
102.86 ± 12.82
97.26 ± 8.47
95.82 ± 7.22

10.74
12.47
8.71
7.54

98.00 ± 7.21
94.15 ± 8.15
98.48 ± 5.20
97.08 ± 8.65

7.36
8.65
5.28
8.91

88.67 ± 10.66
98.48 ± 5.52
91.83 ± 5.82
98.00 ± 7.46

12.02
5.61
6.34
7.61

92.71 ± 8.20
99.12 ± 7.51
97.20 ± 5.55
100.26 ± 10.24

8.84
7.58
5.71
10.21

93.12 ± 9.16
97.25 ± 7.09
95.84 ± 5.98
98.45 ± 8.43

9.84
7.29
6.24
8.56

96.88 ± 9.88
93.25 ± 8.91
101.67 ± 6.39
96.33 ± 7.23

10.19
9.56
6.29
7.50

98.20 ± 13.62
92.72 ± 11.01
98.55 ± 7.53
95.45 ± 8.96

13.87
11.87
7.64
9.39

100.42 ± 11.60
97.00 ± 10.66
95.77 ± 7.43
100.38 ± 7.41

11.55
10.99
7.76
7.39

98.50 ± 11.18
94.32 ± 9.81
98.66 ± 7.15
97.39 ± 7.75

11.35
10.40
7.25
7.96

Table 5
Extraction Recovery (Mean ± SD) of SMV, SMV-A, ATV, 2-OH-ATV, 4-OH-ATV, and RSV at Three Levels of QC Samples from Human Plasma with either Low or High Triglyceride
levels Using Liquid-liquid Extraction Method.
Low TG Levels

High TG Levels

Concentration (ng/ml), n = 6

0.5

5

80

0.5

5

80

SMV
SMV-A
ATV
2-OH-ATV
4-OH-ATV
RSV

99.69 ± 5.28
88.49 ± 6.48
98.84 ± 6.77
92.15 ± 6.20
99.17 ± 6.33
87.99 ± 6.28

98.37 ± 4.42
96.04 ± 6.01
96.94 ± 7.86
97.71 ± 4.52
97.97 ± 8.92
94.62 ± 6.67

99.82 ± 7.31
94.32 ± 4.80
100.37 ± 8.18
96.31 ± 4.17
96.97 ± 9.60
95.36 ± 4.75

95.21 ± 10.05
91.29 ± 3.21
93.06 ± 8.21
94.93 ± 12.20
94.86 ± 12.82
97.77 ± 10.42

97.26 ± 8.83
96.46 ± 3.80
96.41 ± 4.99
95.29 ± 2.52
96.67 ± 9.51
94.18 ± 4.41

97.40 ± 6.80
97.75 ± 5.89
97.36 ± 3.03
96.97 ± 5.03
96.47 ± 8.75
95.28 ± 10.02

Table 6
Matrix Effect (Mean ± SD) of SMV, SMV-A, ATV, 2-OH-ATV, 4-OH-ATV, and RSV at Three Levels of QC Samples from Human Plasma Samples with Low (n = 6 at Each QC Level)
and High (n = 6 at Each QC Level) Triglyceride Levels.
Concentration (ng/ml)
Low TG Levels
0.5
5
80
High TG Levels
0.5
5
80

SMV

SMV-A

ATV

2-OH-ATV

4-OH-ATV

RSV

97.76 ± 4.14
96.61 ± 9.08
96.23 ± 5.93

92.63 ± 7.41
99.98 ± 8.29
103.01 ± 8.48

110.42 ± 6.39
102.78 ± 10.23
97.45 ± 4.40

102.93 ± 8.35
96.50 ± 11.48
99.08 ± 7.15

101.84 ± 9.10
96.06 ± 5.96
97.84 ± 10.47

93.53 ± 2.64
94.64 ± 10.12
93.83 ± 9.04

99.05 ± 6.04
93.62 ± 5.94
97.02 ± 7.49

97.01 ± 7.53
97.85 ± 6.75
101.12 ± 7.99

102.76 ± 9.19
97.05 ± 7.98
94.17 ± 7.42

103.23 ± 13.68
91.59 ± 6.08
101.62 ± 5.74

100.68 ± 8.20
102.52 ± 5.56
97.97 ± 7.99

98.02 ± 8.65
98.20 ± 5.71
97.72 ± 7.40

High TG levels in plasma samples were achieved by spiking with triglycerides to reach ≥ 300 mg/dl (352–403 mg/dl) triglyceride concentrations, t-test showed no statistically
signiﬁcant difference between the matrix effect at all concentration levels between plasma with low and high TG levels.

3.7. Stability
The conditions under which the stability experiments were performed reﬂect the expected conditions during sample preparation,
storage, and analysis. Table 7 presents the results of the stability experiments performed under different conditions. Results of
freeze and thaw stability test showed that all analytes were sta-

ble (92–99%) for three cycles when stored at −80 ◦ C and thawed at
room temperature. Bench-top stability test showed that the samples were stable (90–100%) for 4 h at room temperature (the time
required for sample preparation). Long-term stability test results
showed that the analytes were adequately stable (92–98%) for up to
1 month in plasma when stored at −80 ◦ C. Processed samples can be
analyzed overnight (24 h) in the autosampler at 20 ◦ C without any
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Table 7
Stability of SMV, SMV-A, ATV, 2-OH-ATV, 4-OH-ATV, and RSV in Human Plasma under Various Conditions (n = 6) (RT = Room temperature); All Data are Presented as Mean ± SD.
% of Initial Concentration
Concentration (ng/ml)
SMV
0.5
5
80
SMV-A
0.5
5
80
ATV
0.5
5
80
2-OH-ATV
0.5
5
80
4-OH-ATV
0.5
5
80
RSV
0.5
5
80

Freeze and Thaw, three
cycles, −80 ◦ C to RT

Bench-top, RT for 4 h

Long-term, −80 ◦ C
for 1 month

Processed sample,
autosampler, 20 ◦ C for 24 h

Stock solution,
−20 ◦ C for 1 month

96.92 ± 8.88
94.83 ± 6.84
91.58 ± 5.77

96.75 ± 6.12
97.05 ± 8.45
99.23 ± 8.51

95.62 ± 3.86
94.48 ± 10.69
96.32 ± 5.07

92.30 ± 3.22
94.46 ± 3.00
99.74 ± 2.43

99.98 ± 2.82
94.59 ± 3.18
94.50 ± 4.71

97.22 ± 5.62
98.83 ± 7.36
98.74 ± 2.33

98.97 ± 3.50
99.82 ± 6.69
92.42 ± 5.75

92.75 ± 5.46
98.45 ± 3.37
94.55 ± 7.77

98.68 ± 3.67
95.39 ± 7.87
94.77 ± 5.40

95.53 ± 5.36
94.69 ± 5.79
94.61 ± 5.06

94.43 ± 3.92
95.67 ± 7.45
96.82 ± 3.14

90.35 ± 2.28
93.27 ± 3.81
91.67 ± 1.77

91.67 ± 5.12
98.05 ± 5.95
96.88 ± 8.50

93.21 ± 6.02
94.87 ± 4.40
91.97 ± 3.53

95.17 ± 7.43
95.58 ± 5.97
98.68 ± 11.38

98.38 ± 4.74
93.83 ± 8.69
96.28 ± 4.03

96.75 ± 6.20
98.27 ± 10.90
94.10 ± 6.69

98.00 ± 8.84
92.63 ± 5.67
94.05 ± 3.22

98.12 ± 2.49
96.70 ± 6.84
97.00 ± 6.12

96.82 ± 5.66
94.95 ± 8.75
97.15 ± 7.02

93.55 ± 3.63
96.55 ± 9.10
98.12 ± 9.21

93.63 ± 8.91
96.83 ± 11.15
97.02 ± 7.95

92.95 ± 5.36
95.35 ± 6.25
96.33 ± 7.23

94.62 ± 9.28
98.13 ± 7.10
97.10 ± 5.75

99.78 ± 9.96
98.28 ± 8.96
94.45 ± 4.42

98.8 ± 9.08
96.52 ± 10.42
98.65 ± 6.56

92.85 ± 5.44
97.60 ± 9.34
92.83 ± 5.08

93.78 ± 5.34
97.82 ± 5.47
96.47 ± 7.58

97.12 ± 4.27
96.30 ± 9.38
97.42 ± 8.45

94.87 ± 6.93
95.28 ± 6.30
97.28 ± 5.66

Table 8
Demographic Data of Patients in the Clinical Study.

Racial Breakdown
% (n)

Gender %
(n)
a
b

Mean age (yr)
Caucasian
African American
Hispanic
Other
Male
Female

Statin Group
(n = 26)

Non-Statin
Group (n = 20)

54.4 ± 9.1a
65.4 (17)
19.2 (5)
7.7 (2)
7.7 (2)
42.3 (11)b
57.7 (15)

43.8 ± 11.7
45.0 (9)
25.0 (5)
10.0 (2)
20.0 (4)
10.0 (2)
90.0 (18)

Mean age was signiﬁcantly older in statin group than in non-statin group.
Statin group has a higher % of male patients compared to the non-statin group.

concern about the stability of all analytes (92–100%). Lastly, stock
solutions of the analytes (50 g/ml, each) were stable (94–100%)
up to one month when stored at −20 ◦ C.
3.8. Application
The demographic data of patients is presented in Table 8.
Patients on statins had a mean age signiﬁcantly older than that
of patients not on statins. In addition, statin group has a higher
percentage of males and lower percentage of females compared
to the non-statin group. The developed LC–MS/MS method was
successfully employed for the quantiﬁcations of SMV, ATV, RSV,
and their active metabolites in clinical plasma samples collected
from the obese patients prior to and post-GBS. The concentrations
of all three statins and their active metabolites (ng/ml) were converted to the molar concentration (nM), then were normalized by
dose/body weight [(nM)/(mg/kg)]. The plasma concentrations for
SMV, SMV-A, ATV, 2-OH-ATV, 4-OH-ATV, and RSV from three obese
patients pre- and post-surgery are presented in Fig. 3. These data
were collected as a part of another ongoing clinical study.
4. Discussion
Statins are considered the ﬁrst line treatment of hyperlipidemia,
especially for their effect in reducing the risk of atherosclerotic

cardiovascular diseases. Accurate quantiﬁcation of medications
in plasma samples is crucial for the performance of meaningful
pharmacokinetics studies. Matrix effect is one of the biggest challenges in the development of any LC–MS/MS analytical method that
involves a biological matrix as the sample matrix. The challenge of
matrix effect is even greater if the sample source has higher levels of
triglycerides, cholesterol, and other lipids than normal values, and
the levels of lipids may change during the course of treatment, such
as GBS. High lipid contents in the plasma not only cause concerns
about matrix effect, but also speciﬁcity and recovery.
There are many publications on the analysis of a single statin
and its active metabolite or metabolites. LC–MS/MS assay methods were reported for the simultaneous analysis of simvastatin
and simvastatin acid [11–16], but some of these methods had a
relatively long run time (10, 8 and 6.4 min [11,13,15]) with larger
volume of plasma used (475, 300, 1000, 300 l [11–13,16]), compared to our developed method (5 min run with 200 l of plasma).
Finally, most of these method used solid-phase extraction technique for plasma sample preparation [13,12–16], which is labor
intensive, more time consuming and costly than the liquid–liquid
extraction method we used. Analysis methods for the quantiﬁcation of ATV and its two active metabolites, 2-OH-ATV and
4-OH-ATV, have been reported [17–20]. Most of these methods
use solid-phase extraction method [17,18,20] or high plasma volume for the analysis (500, 1000, 1000 l [17–19]). The LLOQ of
most of these methods for the determination of either SMV (ranged
0.05–2.5 ng/ml) and its metabolite (ranged 0.05–5 ng/ml) or ATV
(ranged 0.05–0.2 ng/ml) and its two metabolites (ranged 0.05–0.5
and 0.05–0.2 ng/ml for 2-OH-ATV and 4-OH-ATV, respectively) was
lower than the LLOQ of our developed method (0.25 ng/ml). However, our method has the advantage of quantifying three statins
simultaneously with their active metabolites. In addition, none
of the published methods tested for the matrix effect or validate
the method using plasma with high triglyceride levels (lipemic
plasma). There is only one publication on the simultaneous quantiﬁcation of multiple statins along with their active metabolites
i.e. simvastatin, atorvastatin, lovastatin, and their active metabolites [21], but the method has a relatively long run time of 12 min,
as compared to 5 min of our developed method. In addition, the
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statins, or when lipid levels are expected to change during the time
period of the study. The linear range of this method for all the three
statins and their metabolites is 0.25 (LLOQ) −100 ng/ml. Sample
preparation and the extraction method (liquid-liquid extraction
using ethyl acetate) were simple and efﬁcient. Extraction recovery was higher than 88% for the three statins and their metabolites
at the three quality control concentration levels from plasma with
low and high triglyceride levels. No signiﬁcant matrix effect for
plasma samples from obese patients was observed even when the
samples were spiked with extra triglycerides to reach triglyceride
levels of more than 300 mg/dl (ranged 352–403 mg/dl). The pharmacokinetic application of this method enables the quantiﬁcation
of SMV, SMV-A, ATV, 2-OH-ATV, 4-OH-ATV, and RSV concentrations in clinical plasma samples, even if they have high levels of
triglycerides. The method was successfully used in another ongoing clinical study of the three statins and their active metabolites
before and after gastric bypass surgery.
5. Conclusion
A sensitive, speciﬁc, accurate, and reliable method was
developed and validated for the simultaneous quantiﬁcation of
simvastatin, simvastatin acid, atorvastatin, 2-hydroxy atorvastatin, 4-hydroxy atorvastatin, and rosuvastatin in human plasma
samples. This is the ﬁrst report of simultaneous quantiﬁcation
of simvastatin, atorvastatin, and rosuvastatin with their active
metabolites. The method has been validated for plasma with low
(<300 mg/dl) and high (>300 mg/dl) triglyceride levels and showed
no interference from the triglycerides with the quantiﬁcation of all
three statins and their active metabolites. The developed method
was successfully used to perform a clinical pharmacokinetic study
of each statin in obese patients who underwent GBS.
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Fig. 3. Plasma concentration proﬁles from obese patients for (a) simvastatin and
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GBS. Molar concentrations were normalized by dose/body weight [(nM)/(mg/kg).
*Pt: patient ID number; 3 M, 6 M and 12 M: 3, 6, and 12 months follow-up visit after
GBS.

validation of this method did not test for the matrix effect in
hyperlipidemic plasma, which is common in obese patients. Elevated levels of triglycerides and cholesterol are common in obese
patients, and it renders the validation with plasma of high triglyceride levels crucial.
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metabolites. The developed LC–MS/MS method in this study is
sensitive, speciﬁc, accurate, precise, and reliable in the quantiﬁcation of three of the most commonly prescribed statins and their
active metabolites. The method is proven to be reliable in quantifying SMV, ATV, RSV and their active metabolites in hyperlipidemic
plasma which is usually encountered in obese patients. This is
especially useful in performing studies that require the analysis
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